Symptomtext
Fevers with a Tmax of 102; Chills; Conjunctivitis; Stocking glove rash to the hands and feet; C-reactive protein increased; Ejection fraction decreased; Red blood cell sedimentation rate increased; Tongue eruption; Troponin I increased; White blood cell count increased; Respiratory Viral Panel; Brain natriuretic peptide; This is a spontaneous report from a non contactable consumer, reports were pulled from the FDA VAERS site by a Pfizer Colleague. The consumer reported for a 17-year-old male patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot Number: none, Expiry Date: not reported),via intramuscular on an unknown site on 26Apr2021 as dose 2, single for covid-19 immunisation. The patient medical history and concomitant medications were not reported. The patient previously received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot Number, Expiry Date: not reported), via an unspecified route on an unspecified date as dose 1, single for covid-19 immunisation. Patient presented 4 days after the start of symptoms, which started 14 days after the second dose of the vaccine. Patient presented with fevers with a Tmax of 102, chills, conjunctivitis, stocking glove rash to the hands and feet, C-reactive protein increased, ejection fraction decreased, red blood cell sedimentation rate increased, tongue eruption, troponin I increased, white blood cell count increased, respiratory viral panel, brain natriuretic peptide on an unknown date in 2021. The patient was hospitalized for 3 days due to all events on an unspecified date and all events were considered as life-threatening. The patient did not visit emergency room or physician office. The patient underwent lab tests and procedures on an unspecified date in 2021 which included body temperature: 102, brain natriuretic peptide: unknown, c-reactive protein: increased, ejection fraction: decreased, red blood cell sedimentation rate: increased, respiratory viral panel: unknown, sars-cov-2 test: negative, troponin i: increased, white blood cell count: increased. The outcome of all event was recovered on unspecified date in 2021. No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.